帕金森病合并异动症患者血浆维生素B12水平的相关因素研究

被引:1
作者
王丽
王小平
李庭毅
机构
[1] 孝感市中心医院神经内科
关键词
帕金森病; 异动症; 维生素B12; 叶酸; 同型半胱氨酸; 左旋多巴;
D O I
暂无
中图分类号
R742.5 [震颤麻痹综合征];
学科分类号
摘要
目的观察维生素B12(vitamin B12,VitB12)、叶酸(folic acid,FA)、同型半胱氨酸(homocysteine,Hcy)在帕金森异动症患者血浆中的变化,分析VitB12水平变化的相关因素。方法237例帕金森病患者根据异动症定义分为异动症组(63例)和非异动症组(174例),比较2组血浆VitB12、FA、Hcy水平,将差异有统计学意义的指标选出,异动症组按性别、年龄、起病年龄、病程、左旋多巴使用时间、日多巴总量、H-Y分期分组,并进行组间对比。结果异动症组血浆Hcy、FA水平与非异动症组比较差异无统计学意义(P>0.05)。异动症组血浆VitB12水平与非异动症组比较差异有统计学意义(P<0.01)。异动症组中不同性别、年龄、起病年龄、病程、使用多巴时间及H-Y分期患者血浆维生素B12水平无明显差异(P>0.05),而不同日多巴总量患者血浆VitB12水平差异有统计学意义(P<0.05),且日多巴总量越大,血浆VitB12水平越低。结论帕金森病异动症患者血浆VitB12水平明显降低,影响异动症患者血浆VitB12变化的因素为日多巴总量。
引用
收藏
页码:961 / 965
页数:5
相关论文
共 23 条
[1]  
The Effect of Hyperhomocysteinemia on Motor Symptoms, Cognitive Status, and Vascular Risk in Patients with Parkinson’s Disease[J] . Bilge Kocer,Hayat Guven,Isik Conkbayir,Selim Selcuk Comoglu,Sennur Delibas,Ivan Bodis-Wollner.Parkinson’s Disease . 2016
[2]   Parkinson's disease related dyskinesia in a Tanzanian population [J].
Dotchin, Catherine L. ;
Gray, William K. ;
Dewhurst, Felicity ;
Massawe, John ;
Chaote, Paul ;
Walker, Richard W. .
PARKINSONISM & RELATED DISORDERS, 2015, 21 (09) :1109-1110
[3]   Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias [J].
Stathis, Pantelis ;
Konitsiotis, Spiridon ;
Antonini, Angelo .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (02) :207-213
[4]  
Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions[J] . Rolf Heumann,Rosario Moratalla,Maria Trinidad Herrero,Koushik Chakrabarty,René Drucker‐Colín,Jose Ruben Garcia‐Montes,Nicola Simola,Micaela Morelli.J. Neurochem. . 2014 (4)
[5]  
Effects of l -tryptophan on l -DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease[J] . Wai Kin D. Ko,Qin Li,Erwan Bezard.Neuroscience Letters . 2014
[6]  
Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials[J] . M. Chondrogiorgi,A. Tatsioni,H. Reichmann,S. Konitsiotis.Eur J Neurol . 2014 (3)
[7]  
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse[J] . Veronica Francardo,M. Angela Cenci.Parkinsonism and Related Disorders . 2014
[8]  
Levodopa, vitamins, ageing and the neuropathy of Parkinson’s disease[J] . Yusuf A. Rajabally,Jean Martey.Journal of Neurology . 2013 (11)
[9]  
Receptor Heteromers in Parkinsonμs Disease and L-DOPA-Induced Dyskinesia[J] . Chiara Fiorentini,Paola Savoia,Daria Savoldi,Cristina Missale.CNS & Neurological Disorders - Drug Targets . 2013 (8)
[10]  
Wearing Off, Dyskinesia, and the Use of Continuous Drug Delivery in Parkinson’s Disease[J] . Peter Jenner.Neurologic Clinics . 2013